Sancuso 3.1mg/24 Hour Patches / Transdermal
Granisetron
34.3mg
AVEVA DRUG DELIVERY SYSTEMS, INC.
| Pack size | 1's Pouch |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | PHARMATRADE |
| Retail Price | 743.00 AED |
Indications
Sancuso 3.1mg/24 Hour Patches / Transdermal is used for:
Nausea and vomiting, Chemotherapy-induced nausea and vomiting, Post-operative nausea and vomiting
Adult Dose
Chemotherapy Induced Nausea & Vomiting
Oral
1 mg PO 1 hr before chemotherapy, then 1 mg 12 hr after 1st dose; OR 2 mg 1 hr before chemotherapy
IV
0.01 mg/kg/dose infused over 5 min or direct injected over 30 sec, 30 min before chemotherapy
Radiation-Induced Nausea & Vomiting
2 mg PO, 1 hr before radiation treatment
Postoperative Nausea & Vomiting
Prevention: 1 mg (undiluted) IV push over 30 seconds; administer before anesthetic induction or immediately before reversal of anesthesia
Treatment: 1 mg (undiluted) IV push over 30 seconds
Elderly:
Chemotherapy Induced Nausea & Vomiting
Oral: 2 mg 1 hr before chemotherapy, then 1 mg 12 hr after 1st dose; OR 2 mg 1 hr before chemo
IV: 0.01 mg/kg/dose infused over 5 min or direct injected over 30 sec, 30 min before chemotherapy
Radiation-Induced Nausea & Vomiting
2 mg PO, 1 hr before radiation treatment
Postoperative Nausea & Vomiting
Prevention: 1 mg (undiluted) IV push over 30 seconds; administer before anesthetic induction or immediately before reversal of anesthesia
Treatment: 1 mg (undiluted) IV push over 30 seconds
Hepatic impairment
No dosage adjustment required
Child Dose
Chemotherapy Induced Nausea & Vomiting
<2 years: Safey and efficacy not established
2-16 years: As adults; 0.01 mg/kg infused over 5 min or direct inj over 30 sec, 30 min before chemotherapy
Oral administration: Currently FDA-approved for IV administration in children; safety and efficacy of oral administration is not established
Postoperative Nausea & Vomiting
Safety and efficacy not established
Not approved for postoperative N/V in pediatric patients because of lack of efficacy and QT prolongation observed in clinical trials
Renal Dose
Renal impairment
IV
Severe (CrCl <30 mL/min): Total clearance was not affected in patients with severe renal failure who received a single 40 mcg/kg IV dose
PO
No dosage adjustment required
Administration
May be taken with or without food. Take up to 1 hr before chemotherapy.
Contra Indications
Hypersensitivity.
Precautions
Subacute intestinal obstruction or ileus. Moderate to severe hepatic impairment. Congenital long QT syndrome or other risk factors for QT prolongation (e.g. electrolyte abnormalities and cumulative high-dose anthracycline therapy). Pregnancy, lactation.
Lactation: excretion in milk unknown; use with caution
Pregnancy-Lactation
Pregnancy Category: B
Lactation: excretion in milk unknown; use with caution
Interactions
Phenobarbital may induce metabolism of granisetron.
Adverse Effects
Side effects of Granisetron :
>10%
Headache (10-21%)
1-10%
Diarrhea (1-9%), Constipation (3-18%), Asthenia (5%), Somnolence (10%), Sedation (10%), Drowsiness (10%)
Frequency Not Defined
Anxiety, Fatigue, Malaise, Increased LFTs
Mechanism of Action
Granisetron is a selective 5-HT3-receptor antagonist with little or no affinity for other serotonin receptors. It blocks serotonin in the chemoreceptor zone.
Note
Sancuso 3.1mg/24 Hour 34.3mg Patches / Transdermal manufactured by AVEVA DRUG DELIVERY SYSTEMS, INC.. Its generic name is Granisetron. Sancuso 3.1mg/24 Hour is availble in United Arab Emirates.
Farmaco UAE drug index information on Sancuso 3.1mg/24 Hour Patches / Transdermal is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.